🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Semaglutide and GFR improvement — FLOW trial renal endpoints Page 3

Semaglutide and GFR improvement — FLOW trial renal endpoints

Dr.RenalNash Sat, Jun 6, 2026 at 9:15 PM 15 replies 218 viewsPage 3 of 3
SkepticalSean
Member
98
345
Jan 2025
Maine
Jun 8, 2026 at 7:59 AM#11
ingrid_STO said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

38 11DerekSJ_a1c, paige_pharma, emma_london and 35 others
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Jun 8, 2026 at 10:59 AM#12

Clinical perspective, offered as context rather than as advice.

Kidney function labs on renal function — good news for anyone concerned about renal effects:

MarkerBaselineMonth 6Ref Range
eGFR8295>60
Creatinine1.20.90.7-1.3
BUN24167-20
UACR6720<30

The FLOW trial demonstrated renal protective effects of semaglutide. My nephrologist is encouraged by the UACR improvement especially.

39 12sarah_nash92, FitDadDave, RunnerRach and 36 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Jun 8, 2026 at 1:58 PM#13
hans_munich said:
Steady state is the thing most people miss.

Pushing back on hans_munich here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

40 13Dr.NateNeph, PharmD_Rodriguez, julia.endo and 37 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jun 8, 2026 at 4:57 PM#14
Dr.RenalNash said:
FLOW is the relevant trial and it reported a meaningful reduction in kidney-disease progression and related death in people with type 2 diabetes and…

The FLOW trial results on renal function and renal outcomes: semaglutide 1.0mg reduced the composite kidney outcome by 24% (HR 0.76, p=0.0003) in CKD patients with T2DM[1].

The trial was stopped early for efficacy — always a strong signal. GFR decline was 1.16 mL/min/1.73m²/year slower with semaglutide. This positions GLP-1 agonists alongside SGLT2 inhibitors as pillars of cardiorenal protection in T2DM.

References:
[1] Perkovic V, et al. N Engl J Med. 2024.
41 14DebRD_ATL, KristenIndy, MarkLI_maint and 38 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 7:56 PM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Report rather than reply if it drifts again.

42 15PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 39 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register